Cellectis and VitamFero sign five-year licensing agreement
To develop vaccines against parasitic infection
French genome engineering specialist Cellectis and VitamFero have signed a five-year research, development and licensing agreement, under which Cellectis will license its proprietary meganuclease technology to VitamFero to develop a new generation of living attenuated vaccines.
Cellectis will supply VitamFero with preselected meganucleases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
VitamFero is a biotech company of the Genopole portfolio, a French science park near Paris dedicated to life sciences.
Cellectis chief executive Andre Choulika said the firm was delighted to be working with VitamFero in this field to promote the development of a new application of its technology.
Pascal Breton, ceo of VitamFero, added that the agreement strengthens the company’s technological potential in the modification of the genomes of apicomplex parasites.